Table 3.

Phase II and III clinical trials studying Jak inhibitors in atopic dermatitis.

Drug name	Identifier	Status	Phase, administration	Enrollment	Duration
Tofacitinib	NCT02001181	Completed (99)	IIa, topical	69	4-week
Ruxolitinib	NCT03011892	Completed (100)	IIb, topical	307	8-week dose-ranging and additional 4-week optional open-label treatment
	NCT03745638; NCT03745651	Underway (101)	III, topical	1,200	8-week and long-term safety extension period
Delgocitinib	NCT03725722	Recruiting	IIb, topical	250	8-week dose-ranging
Baricitinib	NCT02576938	Completed (102)	II, per os	124	16-week in combination with TCS
	NCT03334396; NCT03334422	Met primary endpoint (103)	III, per os	1,350	16-week
	NCT03334435	Recruiting	III, per os	1,500	52-week to evaluate long-term safety
	NCT03428100	Recruiting	III, per os	500	16-week in those who cannot have cyclosporin
	NCT03435081	Recruiting	III, per os	450	16-week dose-ranging study
	NCT03559270	Recruiting	III, per os	300	2-year in those who have completed NCT03435081
	NCT03733301	Recruiting	III, per os	300	16-week in combination with TCS
Abrocitinib	NCT02780167	Completed, results online	IIb, per os	269	12-week dose-range study
	NCT03796676	Recruiting	III, per os	225, adolescents	12-week with other topical therapy
	NCT03575871; NCT03349060	Recruiting	III, per os	375	12-week
	NCT03422822	Recruiting	III, per os	2,300	Approximately 2 years who have completed a qualifying phase III study
	NCT03627767	Recruiting	III, per os	1,370	Over 40 weeks in those who responded well to an initial 12-week treatment
	NCT03720470	Recruiting	III, per os	700	12-week, efficacy compared to dupilumab at 2 weeks
Upadacitinib	NCT02925117	Completed (104)	III, per os	166	16-week
	NCT03738397	Recruiting	III, per os	650	24-week treatment, 12-week follow-up
	NCT03661138	Recruiting	III, per os	264	Up to 141 weeks, evaluating safety
	NCT03568318	Recruiting	III, per os	810	16-week combined with TCS
	NCT03607422; NCT03569293	Recruiting	III, per os	810	16-week